BridgeMD
New treatment option for Mild to Moderate Hypertension
Official title Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
ClinicalTrials.gov ID: NCT07297797
What this study is testing
What is HRS-9563 Injection?
HRS-9563 Injection is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for mild to moderate hypertension.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- The subject voluntarily signs the informed consent form.
- Male or female, aged ≥ 18 years and ≤ 75 years;
- Patients with mild to moderate hypertension;
- At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \> 130 mmHg, and the 24-hour mean systolic blood pressure...
You likely can't join if
- Secondary hypertension;
- Orthostatic hypotension;
- Type 1 diabetes or poorly controlled type 2 diabetes;
- Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;
- Presence of uncontrolled severe arrhythmia within 6 months prior to screening;
- Suspected allergy to the investigational drug or any of its components;
See the full eligibility criteria
- The subject voluntarily signs the informed consent form.
- Male or female, aged ≥ 18 years and ≤ 75 years;
- Patients with mild to moderate hypertension;
- At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \< 160 mmHg.
- Secondary hypertension;
- Orthostatic hypotension;
- Type 1 diabetes or poorly controlled type 2 diabetes;
- Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;
- Presence of uncontrolled severe arrhythmia within 6 months prior to screening;
- Suspected allergy to the investigational drug or any of its components;
- Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;
- Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
- Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.